Life Cycle Management (LCM) is the set of strategic, regulatory and commercial moves that keep a pharmaceutical product earning long after launch. It is the highest-leverage, lowest-hype growth work in pharma, and most European teams under-invest in it. This article is a field guide from a fractional healthcare operator who runs LCM programmes for small teams, with the Cooper / Betadine engagement as a worked example.
LCM is not line-extension for the sake of it. It is a plan that answers one question: how does this molecule keep creating value for patients, for the payer and for the P&L over its full commercial life?
In practice that means five moves, new indications, new formulations, new geographies, generic defence, and brand repositioning. Each move has its own regulatory path, its own payer story and its own commercial tempo. The LCM plan sequences them.
French pharma teams tend to be launch-heavy. The org chart is built for the first three years of a product, brand manager, medical advisor, market access lead, KAM force. After peak sales, the team shrinks and the product is managed by exception.
Nobody owns the P&L of the molecule over ten years. Medical affairs owns the science, regulatory owns the dossier, brand owns the campaign. The gap between those three is where LCM value leaks.
New indications. Reading the clinical data and the unmet need, identifying where a second or third indication is plausible, and commissioning the evidence plan. Timeline: 18-36 months.
New formulations. Paediatric formulation, patient-friendly device, extended-release form. Timeline: 12-24 months, often shorter than indication work.
New geographies. Sequencing country roll-outs by payer receptivity and clinical readiness, not alphabetical order. Fastest value when the product is already reimbursed in a neighbour market.
Generic defence. The 24 months before loss-of-exclusivity is when pricing, switching, patient support and digital presence either protect share or surrender it. Most teams leave this too late.
Brand repositioning. The audience for a year-1 launch is not the audience for a year-7 brand. Repositioning matches the current use-case, prescriber population and channel mix.
Stryke ran the Betadine LCM programme at Cooper, plus a second major product and the internal PMO. The work covered portfolio arbitration, brand repositioning and project management across marketing, medical and regulatory. The principle: one operator owning the through-line, so the internal team does not have to reinvent sequencing every quarter.
Fractional was the right shape because Cooper did not need a permanent LCM director, they needed senior framing plus operational throughput for a defined window, then a clean handover.
A good plan is short. One page per move, with: the clinical rationale, the regulatory pathway and lead time, the commercial opportunity size, the payer argument, the internal owners, and the go / no-go gate. If a plan cannot be summarised in five pages, it will not be executed.
The plan also names the trade-offs explicitly, which move kills which other move for budget and attention, because LCM without trade-offs is a wish list.
Three situations map cleanly to the fractional model. First, a mid-sized affiliate with a portfolio of mature products and no dedicated LCM lead. Second, a biotech post-launch with no marketing director yet but a need for senior LCM thinking (ORIA Bioscience's Series A positioning work fits this shape). Third, a launch team that needs to build LCM into the brand plan from day one rather than bolt it on at year five.
The first deliverable is not the plan. It is an opportunity map, one slide listing every plausible LCM move for the molecule, with rough size, rough timeline and rough investment. From that map, a management team can decide where to double down and where to defer. The plan comes second.
LCM is the set of strategic, regulatory and commercial moves that extend a pharmaceutical product's value after launch, new indications, new formulations, new geographies, generic defence, and brand repositioning. It is planned work, not reactive work.
French pharma teams are heavily weighted toward launch and sales. Post-launch strategy is often split between medical affairs, brand teams and regulatory, with nobody owning the P&L of the molecule over 10 years. That leaves value on the table.
At launch, not after the first loss-of-exclusivity signal. The best LCM plans are written 18 to 24 months before commercial maturity, because new indications, new formulations and geographic expansion all take 18-36 months to land.
Yes. A fractional healthcare operator is the right profile when the LCM work needs senior strategic framing plus hands-on cross-functional execution, and the internal team does not have a full-time director to own it.
A typical Stryke LCM engagement is 3 to 12 months, 2 to 4 days per week, covering the full plan, opportunity map, regulatory sequencing, promotional repositioning, launch of new indications or formulations, and handover. The Betadine LCM programme at Cooper is a representative example.
Written by Anabelle Sellame, founder of Stryke Consulting, fractional healthcare operator working with AstraZeneca France, Cooper, TechniPharma, ORIA Bioscience, NaturAvignon and others. Book an audit at stryke-consulting.fr/book-audit.